Development and Characterization of Desmoglein-3 Specific T Cells from Patients with Pemphigus Vulgaris

Mong-Shang Lin,* Sue J. Swartz,* Argelia Lopez,* Xiang Ding,* Marcelo A. Fernandez-Vina,† Peter Stasny,§ Janet A. Fairley,*‡ and Luis A. Diaz*‡

*Department of Dermatology, Medical College of Wisconsin, and the †VA Medical Center, Milwaukee, Wisconsin 53226; and ‡Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235

Abstract

Pemphigus vulgaris (PV) is a cutaneous autoimmune disease characterized by blister formation in the suprabasilar layers of skin and mucosae and anti–desmoglein-3 (Dsg3) autoantibodies bound to the surface of lesional keratinocytes and circulating in the serum of patients. This disease can be reproduced in neonatal mice by passive transfer of patients’ IgG, indicating that humoral immunity plays an important role in the pathogenesis of PV. Currently, the role of T lymphocytes in the development of PV is not clear. Here, we report that three immunoreactive segments of the ectodomain of Dsg3 specifically induced proliferation of T cells from PV patients. We found that T lymphocytes from 13 out of 14 patients responded to at least one of three Dsg3 peptides. T cells from controls and other patient groups did not respond to these Dsg3 peptides. The major T cell population stimulated by these Dsg3 peptides was CD4 positive. Dsg3-specific T cell lines and clones were developed and were shown to express a CD4 positive memory T cell phenotype. Upon stimulation, these cell lines and clones secreted a Th2-like cytokine profile. The Dsg3 responses of these T cells were restricted to HLA-DR, and not -DQ and -DP, of the major histocompatibility complex. This information will help to elucidate the cellular immune abnormalities leading to production of pathogenic IgG autoantibodies in patients with PV. (J. Clin. Invest. 1997, 99:31–40.) Key words: pemphigus vulgaris • desmoglein-3 • T lymphocytes • MHC II restriction • cytokines

Introduction

T lymphocytes play a major role in the regulation and induction of specific immune responses against infectious agents that are foreign to the host. T cells are also crucial in keeping the immune system from reacting against self antigens. The inability to regulate or control the reactivity of T cells to self antigens can lead to the initiation and the development of autoimmune diseases.

Pemphigus vulgaris (PV) is an autoimmune skin disease characterized by intraepithelial blisters on the skin and mucous membranes and pathogenic anti-epithelial autoantibodies which recognize the desmosomal glycoprotein desmoglein-3 (Dsg3) (1–3). The blisters in PV are located in the suprabasilar regions of the epidermis (4) and are formed by a process of keratinocyte cell–cell detachment known as acantholysis (1, 4). The anti-Dsg3 autoantibodies in PV are bound to lesional epidermis in vivo and also circulate in the serum of the patients (2). The serum titers of these autoantibodies correlate with disease extent and activity. Several groups have reported that the autoantibody response in PV is polyclonal and predominantly of the IgG4 subclass (5–7), although IgG1 autoantibodies have been detected early in the disease (6). The IgG fractions from sera of PV patients are pathogenic by passive transfer experiments, i.e., when injected intraperitoneally into neonatal BALB/c mice, they reproduce the clinical, histological, and immunological features of the human disease in these animals, indicating that PV autoantibodies play an important role in the pathogenesis of this disease (8).

The target antigen recognized by PV autoantibodies is Dsg3, a 130-kD glycoprotein that belongs to the cadherin superfamilly of cell adhesion molecules (9, 10). Dsg3 is a transmembrane protein localized in the desmosome (11), a structure that is involved in epidermal cell–cell adhesion and, hence, in maintaining the structural integrity of the epidermis. The intracellular domain of Dsg3 appears to interact with a desmosomal plaque component, plakoglobin, linking it to the cytoskeleton, whereas the extracellular domain mediates homophilic interactions that bring about cell adhesion (10, 12). It is the ectodomain of Dsg3 that bears the epitopes that are recognized by pathogenic autoantibodies from the sera of PV patients (13, 14).

Although the relevance of anti-Dsg3 autoantibodies in PV is well defined, the cellular immune mechanisms involved in autoantibody formation, i.e., T and B cell interactions, are mostly unknown. T cells have been implicated in autoimmune diseases such as multiple sclerosis (15), myasthenia gravis (16), and Graves’ disease (17). Disease-specific T lymphocytes from these patients have been shown to recognize self antigens and participate in the initiation or progression of the respective autoimmune disease. Antibody production by B cells requires the participation of T helper (Th) cells in T cell–dependent antibody responses (18–22). During an antigen-driven activation of T cells, they are induced to secrete lymphokines that are crucial in antibody production and Ig isotype switching by B cells.
cells. Since PV is an autoimmune disease mediated by autoantibodies, it is postulated that T lymphocytes participate in the pathogenesis of this disease in the stages leading to the production of pathogenic autoantibodies.

The purpose of this study was to investigate the response of T lymphocytes from PV patients to Dsg3 fusion proteins and to define the properties of Dsg3-specific T cells. In this paper, three segments of the ectodomain of Dsg3 that specifically induce proliferation of T cells from PV patients were identified. Moreover, only the CD4, but not the CD8, population of T lymphocytes proliferated in response to Dsg3. The Dsg3-specific T cell lines and clones derived from PV patients maintained antigen specificity in culture. The recognition of Dsg3 epitopes by these T cell clones was restricted to HLA-DR. Dsg3-specific T cells expressed a CD4 memory T cell phenotype and a Th2-like cytokine profile. These findings suggest that CD4 positive T lymphocytes and the Th2 cytokine profile of these cells may modulate the pathogenic autoantibody response in PV patients.

**Methods**

**PV patients and controls.** Sera and PBMC were obtained from 14 PV patients. These 14 patients fulfilled the clinical, histologic, and immunofluorescent (IF) criteria of PV and were followed at the dermatology departments of the Medical College of Wisconsin and the University of Cincinnati. All PV patients showed PV autoantibody titers as determined by indirect IF against human skin and monkey esophagus substrates. Patients with other cutaneous autoimmune diseases such as pemphigus foliaceus (PF) (n = 6), bullous pemphigoid (BP) (n = 3), cicatricial pemphigoid (CP) (n = 2), and psoriasis (n = 4) were included along with normal volunteers (n = 8) as controls.

**Antibodies and cell lines.** Antibody-producing hybridoma cell lines OKT3 (anti-CD3), OKT4 (anti-CD4), OKT8 (anti-CD8), and 7G7B6 (anti–IL-2 receptor [anti–IL-2r]) were purchased from American Type Culture Collection (Rockville, MD). These antibodies were purified from mouse ascites by protein G chromatography. The IL-6 sensitive cell line B9 (25) was a generous gift from Dr. Luciden Aardon (Central Laboratory of the Netherlands). This cell line was cultured in 10% FBS RPMI 1640 medium supplemented with 50 U/ml of IL-6 (Biosource International, Camarillo, CA). The IL-2/IL-4 sensitive cell line HT-2 was obtained from Dr. Robert Fritz (Department of Microbiology, Medical College of Wisconsin) and cultured in 10% FBS RPMI 1640 medium containing 20 U/ml of human recombinant IL-2 (rIL-2). The human rIL-2 was purified from a baculovirus vector (NABI, Miami, FL) for the T cell proliferation assays.

**T cell proliferation assays.** 10^4 purified T lymphocytes were cultured with 10^4 irradiated (2,500 rad) PBMC in the presence of anti-CD3 and anti-CD2 antibodies, respectively, according to the manufacturer’s instructions (29). The purity of isolated cells was > 98% as determined by flow cytometric analysis (not shown). The purified T cells were washed with medium three times and resuspended in RPMI 1640 medium supplemented with 10% human AB serum (NABI, Miami, FL) for the T cell proliferation assays.

**Isolation of PBMC and purification of CD4 and CD8 positive T cells.** PBMC were isolated by Ficoll-Hypaque (Pharmacia) density gradient separation (27). T cells were purified by E-rosetting using 2-aminoethylisothiouronium bromide (Sigma)-treated sheep red blood cells (Colorado Serum Co., Denver, CO) (28). CD4+ or CD8+ T lymphocytes were further negatively selected from the total T cell population by a magnetic sorter (Miltenyi Biotec, Auburn, CA) using anti-CD8 or anti-CD4 antibodies, respectively, according to the manufacturer’s instructions (29). The purity of isolated cells was > 98% as determined by flow cytometric analysis (not shown). The purified T cells were washed with medium three times and resuspended in RPMI 1640 medium supplemented with 10% human AB serum (NABI, Miami, FL) for the T cell proliferation assays.

**Preparation of Dsg3 fusion proteins.** The Dsg3 fusion proteins used in this study are shown in Fig. 1. Five Dsg3 fusion proteins were prepared encompassing the following segments: A (amino acids [AA] 145–192), B (AA 240–303), C (AA 570–614), D (AA 760–793), and E (AA 794–827). Peptides A, B, and C represent segments of the ectodomain and D and E represent the intracellular domain of Dsg3. Control fusion proteins include glutathione-S-transferase (GST) and the SA peptide which encompasses 48 amino acids of the BP180 ectodomain. The BP180 antigen is a hemidesmosomal protein recognized by BP autoantibodies (25). All fusion proteins were soluble in commonly used buffers. Briefly, the fusion proteins were derived by subcloning PCR products of Dsg3 into the 3’ end of the Schistosoma japonicum GST gene in the prokaryotic expression vector, pGEX-2T (Pharmacia LKB Biotechnology, Piscataway, NJ) as described previously (25). Recombinant proteins encoded by the series of Dsg3 expression constructs were expressed in Escherichia coli strain DH5α and purified by glutathione-agarose affinity chromatography (26). These fusion proteins were dialyzed against PBS, concentrated by ultrafiltration, and filter-sterilized. The protein concentration was determined by Bradford protein assays (Bio-Rad, Hercules, CA).

**Figure 1.** Dsg3 fusion proteins. Dsg3 contains five major cadherin-like domains on the extracellular portion. The black strips are the Ca²⁺ binding sites. The locations of Dsg3 fusion proteins used in this study are shown as horizontal bars.
presented as average cpm ± SD. A stimulation index (SI) (cpm of cells treated with fusion proteins/cpm of cells treated with GST at the same concentration) ≥ 3 was considered as a positive response.

Development of Dsg3-specific T cell lines and clones from PV patients. PBMCs from PV patients were cultured with 20 μg/ml of Dsg3 fusion proteins at a density of 2 × 10^6/ml in 24-well plates in RPMI 1640 medium supplemented with 10% human AB serum for 7 d at 37°C. Viable T cells were collected by Ficoll-Hypaque separation and restimulated with 20 μg/ml of Dsg3 antigens in the presence of irradiated autologous PBMC for 7 d. This stimulation procedure was repeated three times. At the last cycle, rIL-2 at the concentration of 10 U/ml was added to T cell cultures 2 d after antigen stimulation.

The resultant T cells were cloned by limiting dilution (30) in the presence of 20 μg/ml of antigen, 30 U/ml of rIL-2, and irradiated autologous PBMC. The T cell lines and clones were maintained by culturing with antigen (20 μg/ml) and rIL-2 and restimulated every 7–10 d using irradiated autologous PBMC (2 × 10^6/well) and/or EBV-transformed cells (31) as antigen-presenting cells (APC).

Antigen responses and MHC class II restriction of Dsg3-specific T cells. The antigen specificity of derived T cell lines and clones was examined by culturing 5 × 10^5/ml T cells with 5 × 10^6/ml of irradiated autologous PBMC in the presence of 20 μg/ml of antigens or with antigen-pulsed EBV-transformed B cells for 5 d at 37°C in 96-well plates (final volume 200 μl). T cells in each well were pulsed with 1 μCi of [3H]thymidine during the last 18 h of incubation. An SI ≥ 3 was considered as a positive response. PHA at 0.25 μg/ml or IL-2 at 10 U/ml were used as the positive controls in these proliferation assays.

The MHC class II restriction of antigen responses of PV T cell lines and clones was determined by using anti–HLA-DR, -DQ, and -DP antibodies at concentrations of 1 μg/ml in proliferation assays. Mouse IgG1 was used as a control in these assays. Antibodies were dialyzed against PBS before being used in cell cultures. It was noted that all three antibodies at the concentration used in proliferation assays were documented as sufficient to saturate binding on at least 10^5 APC. The HLA-DR restriction element of Dsg3-specific T cell clones was analyzed further using a panel of EBV-transformed B cell lines expressing different HLA-DRB1 alleles as APC in the T cell proliferation assays. EBV-transformed cells expressing HLA-DRB1*0101, 0401, 0402, 0405, 0407, 0701, 1401, 1402, and 1501 were used in these experiments.

Surface phenotype of Dsg3-specific T cells. The surface expression of CD3, CD4, CD8, CD19, CD45RA, CD45RO, and TCRα/β on Dsg3-specific T cells was examined by flow cytometric analysis using a FACScan® flow cytometer (Becton-Dickinson) and specific monoclonal antibodies. Mouse IgG was used as a negative control. Fluorescein-conjugated goat F(ab)_2 anti-mouse Ig was used as the secondary antibody.

Lymphokine profile of Dsg3-specific T cells. 10^5 T cells per well were cultured in a 24-well plate in the presence of 10 ng/ml of PMA (Sigma) and 100 ng/ml of anti-CD3 antibodies (32). Cell culture supernatants were collected after 30 h of stimulation, and were subjected to lymphokine bioassays.

The IL-2 or IL-4 bioactivities were determined by the proliferation of HT-2 cells (33) as measured by the uptake of [3H]thymidine. When IL-2 and/or IL-4 is present in the culture supernatant of activated T cells, the proliferation of HT-2 cells is inhibited by anti–IL-2 or anti–IL-4 antibodies, respectively. For IL-2 and IL-4 assays, 1,000 HT-2 cells in 100 μl volume of 10% FBS medium were seeded in wells of 96-well flat-bottom plates. 10 μl of supernatant from activated T cell cultures and anti–IL-2r, anti–IL-4, or control antibodies at a final concentration of 1 μg/ml were added to each well. The HT-2 cell cultures were allowed to grow for 48 h and then pulsed with 1 μCi/well of [3H]thymidine during the last 8 h of incubation.

For IL-6 assays, 5,000 B9 cells were cultured in 100 μl with 10 μl of supernatants from activated T cells in 96-well flat-bottom plates for 2 d. Cells in each well were pulse with 1 μCi of [3H]thymidine during the last 8 h of incubation. The bioactivity of IL-6 was determined by the proliferation of B9 cells.

The presence of γ-IFN in the activated T cell culture supernatants was determined by an ELISA kit (Genzyme Corp., Cambridge, MA) following the manufacturer’s instructions.

MHC class II and ethnic background of PV patients. The analysis of HLA-DRB1 and DQB1 of PV patients was carried out by the use of the sequence specific oligonucleotide hybridization technique of PCR-amplified DNA (34, 35). The usage of HLA-DRB1 and DQB1 and ethnic background of PV patients is shown in Table I.

Results

Responses of PV T lymphocytes to Dsg3 fusion proteins. To examine whether T lymphocytes respond to Dsg3 fusion proteins in proliferation assays, T cells were purified from PBMC of PV patients by E-rosetting. Initial testing of five Dsg3 fusion proteins (described in Methods) to examine the T cell responses from three PV patients (EG, LS, and RS) revealed that only the three proteins of the Dsg3 ectodomain (A, B, and

Table I. HLA-DR and -DQ Typing, Ethnic Backgrounds, and Dsg3 Responses of Patients with PV

<table>
<thead>
<tr>
<th>Patients</th>
<th>HLA-DR</th>
<th>HLA-DQ</th>
<th>Ethnic background</th>
<th>Dsg3M145-192</th>
<th>Dsg3M240-303</th>
<th>Dsg3S517-614</th>
</tr>
</thead>
<tbody>
<tr>
<td>JM</td>
<td>0402/1401</td>
<td>0302/0503</td>
<td>Slovak</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>RD</td>
<td>0402/1602</td>
<td>0302/0502</td>
<td>Mexican</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>MP</td>
<td>0402/1101</td>
<td>0302/0502</td>
<td>Jewish</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>UP</td>
<td>1404/1502</td>
<td>0503/0601</td>
<td>Indian</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>EG</td>
<td>0402/1401</td>
<td>0302/0503</td>
<td>Jewish</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>WE</td>
<td>0402/1401</td>
<td>0302/0503</td>
<td>1/16 Jewish</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>LB</td>
<td>0402/0402</td>
<td>0302/0302</td>
<td>Ashkenazi Jewish</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>LS</td>
<td>0402/1302</td>
<td>0302/0604</td>
<td>Hungarian</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NW</td>
<td>1401/1401</td>
<td>0503/0503</td>
<td>Polish</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>RS</td>
<td>1401/1501</td>
<td>0503/0602</td>
<td>German</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>WAF</td>
<td>0701/1401</td>
<td>0201/0503</td>
<td>Italian/Croatian</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MLC</td>
<td>1401/1501</td>
<td>0503/0602</td>
<td>Dutch</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>EF</td>
<td>0301/0701</td>
<td>0201/0201</td>
<td>Jewish</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ML</td>
<td>ND</td>
<td>ND</td>
<td>Ashkenazi Jewish</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

ND, not done; –, no response; +, T lymphocytes proliferate to Dsg3 peptides.
C) (Fig. 1) induced proliferation of PV T lymphocytes consistently. The peptides D and E which located in the intracellular domain of Dsg3 do not induce proliferation of T cells from PV patients. As shown in Fig. 2A, these three immunogenic Dsg3 segments were capable of inducing proliferation of T lymphocytes in a dose-dependent manner. The optimal proliferative response of PV T cells was obtained using an antigen concentration of 20 μg/ml. These observations were further extended to a group of 14 PV patients. We found that T cells from 10 patients responded to Dsg3 peptide A (AA 145–192), 11 patients responded to peptide B (AA 240–303), and 13 patients reacted with peptide C (AA 570–614) (Fig. 2B and Table I). The stimulatory index of PV T cells to these Dsg3 peptides ranged from 3 to 87. T cells from only one patient did not respond to any of these Dsg3 peptides. The Dsg3 antigenic response of PV T cells was specific, i.e., these cells were unresponsive to GST antigen and other unrelated epidermal antigens such as SL1 of the BP180 antigen that were prepared by the same method (not shown). T cells from the control groups, including patients with BP (n = 3), CP (n = 2), and psoriasis (n = 4), as well as normal volunteers (n = 8), did not respond to any of the Dsg3 fusion proteins (Fig. 2B). Thus, these experiments demonstrate that T cells from the majority of PV patients specifically respond to one or more Dsg3 fusion proteins. Interestingly, T cells from two of six PF patients responded to Dsg3 peptide B (AA 240–303), a region of the molecule that shares ~52% homology with Dsg1, the target antigen in PF.

**CD4+ T cell population responds to Dsg3 fusion proteins.** To further investigate which T cell population is responsible for Dsg3-induced proliferation, CD4 and CD8 positive T cells were isolated using a magnetic cell sorter and further analyzed using the proliferation assay. As shown in Fig. 3A, CD4+ T cells from a PV patient responded to Dsg3 peptides in a dose-dependent manner. CD4+ T cells from 13 PV patients re-
sponded to at least one of these Dsg3 peptides. CD8+ T cells
from the same PV patients showed a typical proliferation re-
sponse to the T cell mitogen PHA and IL-2 (not shown), but
failed to proliferate in response to the Dsg3 peptides (Fig. 3
B). CD8+ T cells from all 14 PV patients did not respond to
Dsg3 antigens. These results strongly suggest that CD4 posi-
tive T lymphocytes are the major T cell population involved in
the autoimmune responses in these patients.

Antigen specificity of Dsg3-specific T cell lines and clones.
To study the properties of Dsg3-specific T lymphocytes, anti-
gen-specific T cell lines were generated from four PV patients
(MLC, WAF, EG, and NW) using the three immunoreactive
Dsg3 fusion proteins listed above. T cell clones were subse-
quently derived from cell lines by limiting dilution. The anti-
gen specificity of these T cell lines and clones to Dsg3 peptides
was confirmed by the proliferation assay. As shown in Fig. 4,
WAF-1 and WAF-2, two T cell clones developed from a PV
patient, specifically responded to the Dsg3 peptide originally
used to derive these clones but did not proliferate with other
Dsg3 fusion proteins. Similarly, T cell lines and clones derived
from other PV patients also specifically responded to the Dsg3
fusion proteins that had been originally used to derive the anti-
gen-specific T cells (SI = 4–135). These results demonstrate
that PV T cell clones maintain their antigen specificity in vitro.

MHC II restriction of Dsg3-specific T cells. To investigate
the MHC II restriction of Dsg3-specific responses of T cell
clones developed from PV patients, anti–HLA-DR, -DQ, and
-DP antibodies were introduced in T cell proliferation assays.
Nonspecific mouse IgG1 was used as an isotype control. As
demonstrated in Fig. 5 A, only the anti-DR antibody, but not
anti-DQ or -DP antibodies, inhibited the proliferation re-
sponse of Dsg3-specific T cell clones to recombinant Dsg3

Figure 3. CD4+ T cells involved in the autoimmune response in
PV patients. The response of CD4+ (A) and CD8+ (B) T cells
to Dsg3 fusion proteins was determined by T cell proliferation
assays as described. Data were expressed as average cpm±SD.
peptides, indicating that the recognition of Dsg3 by PV T cells is restricted to HLA-DR. In five individual Dsg3-specific clones and two cell lines that were tested, all exhibited antigen responses restricted to HLA-DR. Anti–HLA-DQ antibodies in some experiments partially blocked Dsg3-induced T cell proliferation (< 10%); however, this degree of inhibition was far lower than that induced by anti-DR antibodies. To examine which DR allele is the restricted element for Dsg3 antigen presentation, proliferation of T cell clone WAF1 was examined using a panel of EBV-transformed cells as APCs. As shown in Fig. 5 B, Dsg3-pulsed APCs expressing either DRB1*1401 or DRB1*0402 were effective in activating this T cell clone, suggesting that both alleles may be important for autoimmune T cell responses in PV.

Cell surface phenotype and cytokine profile of Dsg3-specific T cells. Flow cytometric analysis was used to determine the cell surface phenotypes of the Dsg3-specific T cells. As shown in Fig. 6, EG3.20, a representative Dsg3-specific T cell clone, expressed CD3, CD4, CD45RA, and TcRβ, but was negative for CD8, CD45RA, and the B cell marker CD19. This result shows that Dsg3-specific T lymphocytes carry a CD4 memory T cell phenotype. Other Dsg3-specific T cell lines and clones from PV patients exhibited the same phenotype (not shown).

The cytokine profile of the Dsg3-specific T cells was determined as follows. T cells were activated by anti-CD3 antibodies in the presence of PMA for 30 h. The activity of IL-2, IL-4, IL-6, and γ-IFN in the T cell culture supernatants was then examined by cytokine bioassays or the ELISA method. As summarized in Table II, Dsg3-specific T cell clones secrete IL-4 and IL-6, but not IL-2 and γ-IFN, suggesting that these T cells express a Th2-like lymphokine profile.

Discussion

This investigation demonstrates that T cells from PV patients proliferate when incubated with antigenic peptides derived from the extracellular domain of Dsg3 presented by autologous APCs. The T cells of only one patient (LB), out of the 14 tested, failed to respond to any of the Dsg3 peptides. This patient was receiving high doses of steroids and immunosuppressive therapy at the time her cells were obtained for analysis.

Since the Dsg3 peptides were prepared as bacterial GST fusion proteins, it was important to test GST for T cell proliferative activity. T cells from PV patients remained unreactive when incubated with GST or GST conjugated to other unrelated epidermal-derived antigens, such as Sa1 of the BP180 antigen (25). The PV T cell proliferative response to Dsg3 fusion proteins was dose dependent. The control group, which included T cells from three BP patients, two cases of CP, four cases of psoriasis, and eight healthy individuals, did not proliferate when incubated with these Dsg3 fusion proteins. It was noted that T cells from two PF patients (n = 6) also responded to Dsg3 peptide B (AA 204–303). It appears likely that a subpopulation of T cells from certain PF patients may recognize epitopes within this region of Dsg3 due to the high degree of sequence identity (52%) between Dsg3 and Dsg1 (the PF antigen) at the level of the peptide.

This study showed that T cells from the majority of PV patients recognize peptide C (AA 570–614) of the Dsg3, suggesting that this region of the molecule may contain epitopes that

<table>
<thead>
<tr>
<th>T cell lines</th>
<th>IL-2</th>
<th>IL-4</th>
<th>IL-6</th>
<th>γ-IFN</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG3</td>
<td>Undetectable</td>
<td>5.2±0.2</td>
<td>61.7±5.4</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>EG4</td>
<td>Undetectable</td>
<td>5.7±0.5</td>
<td>47.8±19.6</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>MLC1</td>
<td>Undetectable</td>
<td>8.4±0.6</td>
<td>18.0±2.3</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>NW1</td>
<td>Undetectable</td>
<td>13.4±3.4</td>
<td>17.4±4.5</td>
<td>&lt; 3 pg/ml</td>
</tr>
</tbody>
</table>

T cell clones

<table>
<thead>
<tr>
<th>T cell clones</th>
<th>IL-2</th>
<th>IL-4</th>
<th>IL-6</th>
<th>γ-IFN</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG3.20</td>
<td>Undetectable</td>
<td>59.0±22.2</td>
<td>53.2±8.3</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>EG6.17</td>
<td>Undetectable</td>
<td>23.7±1.5</td>
<td>71.2±1.2</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>WAF1</td>
<td>Undetectable</td>
<td>6.0±0.4</td>
<td>21.9±1.7</td>
<td>&lt; 3 pg/ml</td>
</tr>
<tr>
<td>WAF2</td>
<td>Undetectable</td>
<td>11.5±4.1</td>
<td>69.5±0.4</td>
<td>&lt; 3 pg/ml</td>
</tr>
</tbody>
</table>

IL-2, IL-4, and IL-6 were determined by bioassays as described in Methods. Concentrations of IL-4 and IL-6 were expressed as U/ml. γ-IFN was measured by ELISA.
are strongly immunogenic. However, in some patients, Dsg3 peptide A (AA 145–192) produced the strongest proliferation response. The diversity of T cell responses to Dsg3 fusion proteins was further demonstrated by the observation that PV patients, although expressing the same or similar MHC class II alleles, respond to different Dsg3 peptides (Table I). It is possible that the initial immune response in PV patients is directed against a single, common epitope on Dsg3 and later spreads to other epitopes located on other domains of the molecule. However, the initial epitope that triggers the autoimmune response in PV patients remains unknown. This “determinant spreading” phenomenon is a consideration in PV, since it has been documented in other autoimmune diseases such as EAE and spontaneous insulin-dependent diabetes in the nonobese diabetic mouse (36–38).

Comparing the sequence of Dsg3 peptides that were used for PV T cell response analysis by Wucherpfennig et al. (39) with the Dsg3 fusion proteins used in this study, we found that only peptide B (AA 204–303) contains a short stretch of complete homology with a peptide used by these investigators (Dsg3#206-220). Currently, we have derived individual T cell clones responding to different segments of Dsg3 from four PV patients. Each of these T cell clones only responds to the one Dsg3 peptide that had been used to derive the respective clone as shown in Fig. 4. Thus, these results suggest that the T cell response against Dsg3 in PV is polyclonal and represents part of the complex spectrum of PV reactivity to self antigens. It is possible that other regions of Dsg3, which were not included in this study because of the insolubility of the fusion proteins containing these regions (region 1–144, 193–239, 304–569, 615–
Lin et al. (759, and 828–1087), may possess other as yet undisclosed T cell epitopes that may also be relevant in the pathogenesis of PV. Work is in progress to define epitopes along the whole length of Dsg3.

Although different Dsg3 epitope–specific T cell lines and clones were obtained from PV patients, it is not clear which of the Dsg3 epitopes is responsible for enhancing B cell activation and production of pathogenic anti-Dsg3 autoantibodies. Preliminary testing of the T cell clones specific for the Dsg3 peptide A (AA 145–192) shows that they weakly stimulate autologous B cells in vitro to produce antiepidermal autoantibodies as determined by indirect IF (Lin, M.-S., et al., manuscript in preparation). This encouraging finding suggests that this Dsg3 segment may contain the epitope(s) relevant in the interaction of T and B cells in PV. As a following to this observation, overlapping synthetic peptides that cover segment A of Dsg3 were used to map a single 15–amino acid stretch that is responsible of stimulating T cell clones EG3.20 and WAF1.

Contrary to a recent preliminary report, we presented evidence that CD4 positive T lymphocytes are the major T cell population responding to Dsg3. This conclusion was supported by the cell surface phenotype of Dsg3-specific T cell lines and clones derived from four patients. These T cells express a CD4+ memory T cell phenotype. The report by Hertl et al. (see reference 50) showed that CD8 positive T lymphocytes from PV patients with the HLA-DR11 haplotype reacted with recombinant Dsg3, suggesting that CD8+ T cells may also participate in the immune response in some PV patients.

The majority of PV patients included in this study exhibit either DRB1*0402 or 1401 or both alleles (Table I). These two DR alleles have strong association with the occurrence of PV in both Jewish and non-Jewish PV populations (40–43). It has been shown that antigenic peptides bound by MHC II molecules are promiscuous in binding to several allotypes (44–46), hence, it is conceivable that the same peptides of Dsg3 are bound by both DRB1 alleles associated with susceptibility to PV and presented to T cells. Interestingly, both DRB1*0402 and DRB1*1401 have glutamic acid and valine at position 71 and 86, respectively, of the DRβ subunit. The side chains of these residues have been shown to project into the peptide binding groove and play a crucial role in anchoring the peptides bound (47–49), therefore, suggesting that T cells from PV patients expressing either one of these two alleles may recognize the same Dsg3 peptides. This is in agreement with results reported by Wucherpfennig et al. (39) showing that several antigenic Dsg3 peptides are stimulatory for T cells from PV patients expressing either DRB1*0402 or 1401 alleles. Our results demonstrate unequivocally that T cells from PV patients expressing either one of these two DR alleles respond to three Dsg3 peptides (A, B, and C), supporting the notion that both DR haplotypes are important in the presentation of Dsg3 peptides. However, not all T cells from PV patients expressing these two DR alleles are stimulated by these three peptides, suggesting the autoimmune response to Dsg3 is complex and heterogeneous among PV patients. Similar phenomena have been observed by other investigators (39).
In this report, we demonstrated that the antigenic response of Dsg3-specific T cells was restricted to HLA-DR. This conclusion was initially drawn by the observation that only the anti–HLA-DR antibody, but not anti-DQ or -DP antibodies, blocks the antigenic response of Dsg3-specific T cell clones. We found that only EBV-transformed cells expressing the DRB1*0402 or 1401 were capable of presenting Dsg3 fusion proteins to a Dsg3-specific T cell clone WAF1 (Fig. 5 B), further documenting DR restriction in these responses. Interestingly, clone WAF1 was developed from a PV patient expressing DRB1*1401. These results strengthen the hypothesis that both 0402 and 1401 alleles can present the same Dsg3 peptides to PV T cells and that both alleles are the restricting element for T cell responses to Dsg3 in PV patients. Similar results have been obtained by others (39). However, Hertl et al. (50) showed that the response of Dsg3-specific clones derived from a PV patient expressing HLA-DR11 was restricted to the DQ7 allele rather than to DR11. These seemingly conflicting data indicate that the MHC class II restriction of the Dsg3 presentation may vary from patient to patient in this disease.

The isotype of antibodies produced by a given B cell is dependent on the type of helper T lymphocytes that it encounters during the T–B cell interaction (51, 52). For example, CD4 T cells that secrete Th2 cytokines are capable of inducing B lymphocytes to secrete IgG4 (53). In PV, several groups have demonstrated that IgG4 is the predominant pathogenic autoantibody fraction, suggesting that T cells of the Th2 helper lineage may be relevant in the autoimmune response in these patients (5–7). The findings of this report and those of a previous publication by Wucherpfennig et al. (39) provide strong support for this hypothesis. T cell clones derived from Ashkenazi Jewish PV patients specifically respond to Dsg3 synthetic peptides and secrete IL-4 and IL-10, suggesting that these cells are Th2-like T helper lymphocytes (39). We have further established that our Dsg3-specific T cell clones secrete IL-4 and IL-6, but not IL-2 and γ-IFN. Since the pathogenic autoantibodies in PV are predominantly of the IgG4 subclass, the Th2-type cytokine profile expressed by autoimmune T cell clones derived from these patients suggests that these T cells may modulate the B cell isotype switch in these patients.

Acknowledgments

The authors thank Dr. Robert Truitt (Department of Pediatrics, Medical College of Wisconsin) and Dr. Robert Fritz (Department of Microbiology, Medical College of Wisconsin) for critical review of the manuscript.

This work was supported in part by U.S. Public Health Service grants R37-AR32081, RO1-AR32599, and T32-AR07577 (L.A. Diaz) and RO1-HL47175 (P. Stastny) from the National Institutes of Health. The authors thank Dr. Robert Truitt (Department of Pediatrics, W.F. Lever, editor. C. Charles Thomas, Springfield. 1965. Pemphigus vulgaris. In Pemphigus and Pemphigoid. W.F. Lever, editor. C. Charles Thomas, Springfield.


27. Indiveri, F., J. Huddleston, M.A. Pellegrino, and S. Ferrone. 1980. Iso-


